<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557620</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4215</org_study_id>
    <secondary_id>2014-005171-84</secondary_id>
    <secondary_id>U1111-1164-2741</secondary_id>
    <nct_id>NCT02557620</nct_id>
  </id_info>
  <brief_title>Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare the steady-state
      exposure of semaglutide administered subcutaneously once daily to semaglutide administered
      subcutaneously once weekly in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the semaglutide concentration-time curves</measure>
    <time_frame>At steady-state from 0 to168 hours after dosing on day 78</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed semaglutide plasma concentration</measure>
    <time_frame>At steady-state derived from the concentration-time curves, within 168 hours from day 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline (day 1, post-dose) to last follow-up visit (day 120)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the the single dose concentration-time curve</measure>
    <time_frame>From 0 to 300 min after administration of paracetamol (1.5 g) at day 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the the single dose concentration-time curve</measure>
    <time_frame>From 0 to 300 min after administration of paracetamol (1.5 g) at day 79</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>semaglutide OD + placebo semaglutide OW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo semaglutide OW + placebo semaglutide OD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>semaglutide OW + placebo semaglutide OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin)once daily or once weekly.</description>
    <arm_group_label>semaglutide OD + placebo semaglutide OW</arm_group_label>
    <arm_group_label>semaglutide OW + placebo semaglutide OD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin)once daily or once weekly.</description>
    <arm_group_label>semaglutide OD + placebo semaglutide OW</arm_group_label>
    <arm_group_label>placebo semaglutide OW + placebo semaglutide OD</arm_group_label>
    <arm_group_label>semaglutide OW + placebo semaglutide OD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-55 years (both inclusive) at the time of signing informed
             consent

          -  Considered to be generally healthy based on the medical history, physical examination,
             and the results of vital signs, ECG and clinical laboratory tests performed during the
             screeningvisit, as judged by the investigator

          -  Body mass index (BMI) between 20.0 and 29.9 kg/m^2 (both inclusive)

          -  HbA1c (glycosylated haemoglobin) below 6.5%

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             childbearing potential and not using adequate contraceptive method throughout the
             trial including the 5 weeks follow-up period (adequate contraceptive measures as
             required by local regulation or practice)

          -  Any disorder which in the investigator's opinion might jeopardise subject's safety,
             evaluation of results, or compliance with the protocol

          -  History of pancreatitis (acute or chronic)

          -  Screening calcitonin equal or above 50 ng/L

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary
             Thyroid Carcinoma (MTC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>January 2, 2017</last_update_submitted>
  <last_update_submitted_qc>January 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

